Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer

Published:2007 Issue:5-6 Volume:72 Page:330-337
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Saji Shigehira,Toi Masakazu,Morita Satoshi,Iwata Hiroji,Ito Yoshinori,Ohno Shinji,Kobayashi Tadashi,Hozumi Yasuo,Sakamoto Junichi

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference30 articles.

1. Treatment of Breast Cancer

2. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

3. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

4. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of Cancer Drugs That Cause Fingerprint Loss;Doğu Karadeniz Sağlık Bilimleri Dergisi;2023-11-30

2. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;BMC Cancer;2021-07-05

3. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;2020-08-21

4. Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study;Journal of Nippon Medical School;2020-04-15

5. Dose-finding designs for trials of molecularly targeted agents and immunotherapies;Journal of Biopharmaceutical Statistics;2017-02-06